Q-omics provides the consensus-scored MIR6858 profile across patient tissues and cancer cell-line models. MIR6858 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR6858 is differentially expressed in 3, with the highest sampling consensus in COAD. Additionally, MIR6858 RNA expression shows 4,790 significant gene co-expression associations, with the highest sampling consensus in READ. Together, these results highlight UCS, COAD, and READ as cancer lineages where MIR6858 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR6858 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR6858 survival associations across molecular data types. MIR6858 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR6858 RNA expression–survival associations across cancer types. High MIR6858 expression shows unfavorable associations in UCS, ESCA, UVM, BRCA and DLBC, but favorable associations in BLCA. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for MIR6858 RNA expression.
This table summarizes MIR6858 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR6858. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR6858 shows higher tumor expression in COAD, UCEC and LIHC. The COAD box plot shows higher MIR6858 RNA expression in tumor versus normal tissue (log2 FC = +0.443, t-test p = .006).
This table shows molecular features associated with MIR6858 in patient tissues and cancer cell lines. In patient samples, MIR6858 shows the broadest associations at the RNA and protein expression levels, with READ recurring as the lineage with the largest associated feature set.
